Congenital Nephrotic Syndrome Medical Services in China

Congenital Nephrotic Syndrome (CNS) is a rare, genetically driven kidney disorder presenting within the first three months of life—typically before birth or in the neonatal period. It is characterized by massive proteinuria, severe hypoalbuminemia, hyperlipidemia, and generalized edema, resulting from structural and functional abnormalities in the glomerular filtration barrier, particularly involving podocyte slit diaphragm proteins. The most common genetic cause is autosomal recessive mutations in the NPHS1 gene encoding nephrin, accounting for ~80% of Finnish-type CNS; other implicated genes include NPHS2 (podocin), WT1, LAMB2, and PLCE1. Pathogenesis centers on disrupted podocyte architecture and signaling, leading to loss of size- and charge-selective filtration, permitting uncontrolled leakage of plasma proteins—especially albumin—into the urine. This triggers compensatory hepatic synthesis of lipoproteins and acute-phase reactants, perpetuating edema, thrombotic risk, infection susceptibility, and growth failure. Epidemiologically, CNS is exceedingly rare, with an estimated incidence of 1–3 per 100,000 live births globally; it is markedly higher in Finland (1:8,200) due to a founder NPHS1 mutation. Risk factors are predominantly genetic—consanguinity increases autosomal recessive transmission risk—and prenatal indicators such as elevated maternal alpha-fetoprotein, placental enlargement (>25% of birth weight), and fetal ascites may raise suspicion. Without intervention, CNS carries high mortality in infancy due to sepsis, thromboembolism, malnutrition, and end-stage kidney disease (ESKD). Quality of life is profoundly impacted: affected infants require intensive nutritional support, frequent albumin infusions, anticoagulation, immunosuppression (in select non-genetic or atypical cases), and early nephrectomy followed by dialysis or transplantation. Caregivers face immense psychosocial, financial, and logistical burdens—including prolonged hospitalizations, home nursing, and lifelong immunosuppressive management post-transplant. Even with successful kidney transplantation, recurrence is rare in monogenic CNS but long-term outcomes depend on timing of transplant, infection control, and neurodevelopmental surveillance. Early molecular diagnosis via genetic testing (e.g., targeted NGS panels) is critical to guide prognosis, avoid ineffective immunosuppression, and enable family counseling and prenatal testing in subsequent pregnancies.

Congenital nephrotic syndrome (CNS) is a rare, severe glomerular disorder presenting within the first three months of life, characterized by massive proteinuria, hypoalbuminemia, hyperlipidemia, and edema. It results from structural and functional abnormalities in the glomerular filtration barrier—primarily involving podocytes and the slit diaphragm—and leads to early-onset nephrotic-range protein loss. The overwhelming majority of CNS cases are monogenic, with autosomal recessive inheritance predominating.

The most common genetic cause is pathogenic variants in the NPHS1 gene (chromosome 19q13), encoding nephrin—a critical transmembrane protein essential for slit diaphragm integrity. Over 200 disease-causing mutations have been identified, with the Fin-major and Fin-minor founder mutations accounting for >90% of Finnish cases and ~50% of non-Finnish European cases. Mutations lead to truncated or misfolded nephrin, resulting in absent or disorganized slit diaphragms and profound permselectivity failure. Second most common is mutations in NPHS2, encoding podocin, which anchors nephrin to the podocyte cytoskeleton; NPHS2-related disease typically manifests slightly later (infancy rather than neonatal period) but still qualifies as congenital when onset occurs ≤3 months. Other well-established monogenic causes include WT1 (associated with Denys-Drash and Frasier syndromes, often with gonadal dysgenesis and Wilms tumor risk), LAMB2 (encoding laminin β2, causing Pierson syndrome with ocular and neurological involvement), PLCE1 (phospholipase C epsilon 1, linked to early-onset diffuse mesangial sclerosis), and CD2AP, TRPC6, and INF2 (less frequent, often with variable expressivity and overlapping phenotypes).

Triggers are not applicable in the classical sense, as CNS is fundamentally a developmental disorder—not an acquired immune-mediated or inflammatory condition. However, secondary insults may exacerbate clinical severity: perinatal infections (e.g., congenital syphilis, CMV, toxoplasmosis) can unmask or accelerate proteinuria in genetically predisposed infants; sepsis or volume depletion may precipitate acute kidney injury or thrombotic microangiopathy due to underlying hypercoagulability and endothelial dysfunction. Additionally, iatrogenic factors—including inappropriate use of NSAIDs or ACE inhibitors in neonates—can impair renal perfusion and worsen glomerular barrier function.

Risk factors are predominantly genetic and demographic. Consanguinity significantly increases risk due to higher likelihood of homozygous pathogenic variants, particularly for NPHS1 and NPHS2. Ethnic background influences mutation prevalence: NPHS1 founder mutations are highly enriched in Finnish, Icelandic, and certain Eastern European populations; NPHS2 mutations show higher frequency in Mediterranean and Middle Eastern cohorts. A positive family history of infantile nephrotic syndrome or unexplained neonatal death is a major red flag. Prenatal risk factors include intrauterine growth restriction (IUGR) and oligohydramnios—often secondary to fetal hypoalbuminemia-induced hypoproteinemic edema and reduced fetal urine output—though these are consequences rather than antecedent causes.

Environmental factors play no primary etiologic role in monogenic CNS. However, maternal exposures during pregnancy may modulate phenotypic expression or contribute to differential diagnosis. Maternal autoimmune conditions (e.g., SLE) rarely cause transient neonatal nephrotic syndrome via transplacental anti-podocyte antibodies (e.g., anti-PLA2R), but this is distinct from true CNS and resolves spontaneously. Similarly, maternal drug exposure (e.g., captopril, lithium) has been anecdotally associated with fetal renal anomalies but lacks robust evidence linking it to classic CNS. Importantly, environmental toxins, diet, or postnatal infections do not initiate CNS; however, poor sanitation and limited access to neonatal intensive care increase morbidity and mortality by delaying diagnosis, promoting infection-related complications (e.g., spontaneous bacterial peritonitis, sepsis), and limiting therapeutic options such as timely nephrectomy or transplantation.

In summary, CNS is overwhelmingly driven by germline pathogenic variants disrupting podocyte structure and function. Genetic testing—including targeted gene panels or whole-exome sequencing—is standard of care for diagnosis, prognostication, and family counseling. While no environmental or lifestyle interventions prevent monogenic CNS, early recognition of at-risk populations, prenatal ultrasound surveillance for IUGR/oligohydramnios, and rapid postnatal evaluation of proteinuria enable timely intervention and improve long-term outcomes.

Congenital Nephrotic Syndrome (CNS) is a rare, autosomal recessive disorder characterized by massive proteinuria, hypoalbuminemia, hyperlipidemia, and severe edema presenting within the first three months of life—typically before 90 days. It results from genetic defects in podocyte structural or slit diaphragm proteins, most commonly mutations in NPHS1 (encoding nephrin), followed by NPHS2 (podocin), WT1, LAMB2, and PLCE1. Early symptoms are often subtle but rapidly progressive: neonates may exhibit poor feeding, lethargy, and failure to thrive within the first week; subtle periorbital puffiness or scrotal/labial edema may be noted by day 5–10. A key early red flag is foamy urine—reflecting profound proteinuria—often observed by caregivers during diaper changes. Weight gain disproportionate to intake, due to fluid retention rather than adiposity, is frequently misinterpreted as healthy growth. Respiratory distress secondary to pleural effusions or pulmonary edema may manifest as tachypnea, nasal flaring, or grunting, especially in infants with ascites-induced diaphragmatic compromise.

Typical symptoms emerge by 2–6 weeks of age and define the clinical syndrome: generalized, pitting edema involving face, extremities, abdomen (ascites), and genitalia; severe hypoalbuminemia (<2.0 g/dL) leads to anasarca and skin fragility with increased risk of bullae and infection. Massive proteinuria (>40 mg/m²/h or >3 g/g creatinine on spot urine) is universal and persistent, unresponsive to standard immunosuppression. Hypoalbuminemia drives hepatic overproduction of lipoproteins, resulting in marked hypercholesterolemia (often >500 mg/dL) and elevated triglycerides. Growth retardation becomes evident by 1 month, with weight-for-length falling below the 5th percentile. Hypothyroidism may develop due to urinary loss of thyroid-binding globulin and thyroxine, contributing to hypotonia and bradycardia. Thrombotic complications—including renal vein thrombosis, cerebral sinovenous thrombosis, and pulmonary embolism—are common due to urinary losses of antithrombin III, protein C, and protein S, compounded by hemoconcentration and immobility.

Accompanying symptoms reflect multisystem involvement and metabolic derangements. Recurrent bacterial infections—especially spontaneous bacterial peritonitis, cellulitis, pneumonia, and sepsis—are frequent due to concurrent loss of immunoglobulins (particularly IgG) and complement factors in urine, coupled with impaired opsonization and neutrophil dysfunction. Hypocalcemia (from vitamin D–binding protein loss and reduced intestinal calcium absorption) manifests as jitteriness, tetany, or seizures. Vitamin D deficiency contributes to rickets and delayed motor milestones. Iron deficiency anemia arises from urinary loss of transferrin and chronic inflammation; folate deficiency may occur secondary to urinary folate-binding protein loss. Gastrointestinal manifestations include diarrhea (due to enteric protein loss and mucosal edema), malabsorption, and protein-losing enteropathy. Cardiac findings may include gallop rhythm, hepatomegaly, and signs of high-output heart failure in severe cases. Neurodevelopmental delay is increasingly recognized—not solely attributable to recurrent infections or malnutrition but potentially linked to chronic uremia, cerebrovascular thrombosis, or direct neurotoxic effects of dyslipidemia.

Complications are both acute and chronic. Acute life-threatening complications include septic shock, acute kidney injury (often prerenal or intrinsic due to interstitial nephritis or thrombotic microangiopathy), and intracranial hemorrhage secondary to coagulopathy. Chronic complications encompass end-stage kidney disease (ESKD) invariably developing by age 3–5 years in classic Finnish-type CNS (NPHS1-related); growth failure, osteodystrophy, and delayed puberty are nearly universal without aggressive nutritional and hormonal support. Renal replacement therapy—initially peritoneal dialysis—is required early, but long-term outcomes remain guarded due to high rates of peritonitis and catheter-related complications. Post-transplant recurrence is rare in NPHS1/NPHS2-related disease but occurs in some WT1-associated cases. Cardiovascular morbidity includes accelerated atherosclerosis and left ventricular hypertrophy. Psychosocial burden is substantial, with parental anxiety, caregiver burnout, and developmental delays impacting quality of life.

Diagnosis relies on a multimodal approach. Urinalysis reveals heavy proteinuria (≥3+ on dipstick, confirmed by quantitative urine protein-to-creatinine ratio >2.0 mg/mg in infants <3 months). Serum studies demonstrate hypoalbuminemia (<2.5 g/dL), hyperlipidemia, hypogammaglobulinemia, low antithrombin III, and often elevated serum creatinine (though GFR may initially be preserved). Renal ultrasound typically shows enlarged, echogenic kidneys with preserved corticomedullary differentiation—distinct from obstructive or cystic diseases—but may be normal early. Genetic testing is the diagnostic cornerstone: targeted next-generation sequencing panels for NPHS1, NPHS2, WT1, LAMB2, PLCE1, and COQ2 are recommended as first-line. Skin biopsy for laminin β2 immunostaining aids in diagnosing Pierson syndrome (LAMB2-related). Renal biopsy is generally avoided in early infancy due to procedural risk and limited diagnostic yield—however, if performed, light microscopy shows minimal change or diffuse mesangial hypercellularity; electron microscopy reveals foot process effacement, and immunofluorescence is negative for immune deposits. Prenatal diagnosis is feasible via amniocentesis or chorionic villus sampling when familial mutations are known.

Differential diagnosis must exclude other causes of neonatal nephrotic syndrome and edematous disorders. Minimal Change Disease (MCD) is exceedingly rare before 6 months and lacks the rapid progression and genetic associations of CNS. Hereditary steroid-resistant nephrotic syndrome (e.g., due to NPHS2 mutations) may present slightly later (3–12 months) but overlaps clinically; genetic testing clarifies distinction. Syndromic disorders include Denys-Drash (WT1 mutations: associated with ambiguous genitalia, Wilms tumor, and male pseudohermaphroditism) and Frasier syndrome (WT1 intronic mutations: gonadal dysgenesis, streak ovaries, and late-onset nephrosis). Pierson syndrome (LAMB2) features microcoria and neurodevelopmental delay. Secondary causes—congenital infections (syphilis, CMV, toxoplasmosis), congenital heart disease with renal venous congestion, or severe maternal hypertension—must be excluded via serologic testing, echocardiography, and maternal history. Non-renal mimics include congenital hypothyroidism (elevated TSH, low T4, but no proteinuria), alpha-1-antitrypsin deficiency (hepatomegaly, elevated liver enzymes), and severe malnutrition (low albumin but absence of proteinuria and edema pattern). Accurate differentiation guides prognosis, genetic counseling, transplant planning, and surveillance for extrarenal malignancies.

Congenital Nephrotic Syndrome (CNS) is a rare, autosomal recessive disorder typically presenting within the first three months of life with massive proteinuria, hypoalbuminemia, hyperlipidemia, and severe edema. The most common genetic cause is mutations in the NPHS1 gene encoding nephrin, leading to structural and functional disruption of the glomerular slit diaphragm. Less frequent etiologies include mutations in NPHS2 (podocin), WT1, LAMB2, and PLCE1. Early diagnosis—via urinary protein-to-creatinine ratio (>2–3 mg/mg), serum albumin (<25 g/L), lipid profile, and confirmatory genetic testing—is critical to guide management and prognostication. Treatment is multidisciplinary, involving pediatric nephrology, genetics, nutrition, and transplant services, and must be initiated promptly to mitigate complications including infection, thrombosis, growth failure, and end-stage kidney disease (ESKD).

Conservative treatment forms the cornerstone of early CNS management and aims to stabilize physiology while preserving residual renal function. Strict sodium and fluid restriction (typically 1–2 mEq/kg/day Na⁺ and 60–80 mL/kg/day fluids) is essential to control edema and prevent pulmonary congestion. Albumin infusions (e.g., 1 g/kg IV every other day or weekly, titrated to clinical response) may transiently improve oncotic pressure and reduce ascites/pleural effusions but do not alter disease progression and carry risks of volume overload and allergic reactions. Anticoagulation (e.g., low-molecular-weight heparin at prophylactic doses) is indicated in patients with serum albumin <20 g/L due to high thrombotic risk from loss of antithrombin III and other anticoagulant proteins. Aggressive nutritional support—including high-calorie (120–150 kcal/kg/day), high-protein (3–4 g/kg/day) feeds supplemented with medium-chain triglycerides (to bypass lymphatic protein loss)—is vital to counteract catabolism and promote neurodevelopmental outcomes. Regular monitoring of serum calcium, vitamin D, thyroid hormones, and iron stores is mandatory given frequent deficiencies secondary to urinary losses.

Pharmacologic therapy has limited efficacy in genetically mediated CNS. Corticosteroids and conventional immunosuppressants (e.g., cyclophosphamide, calcineurin inhibitors) are ineffective in NPHS1- and NPHS2-related disease and are not recommended outside of rare, atypical presentations with possible immune-mediated components. However, in patients with WT1-associated CNS (e.g., Denys-Drash syndrome), tumor surveillance and early gonadectomy may be indicated due to gonadoblastoma risk. Emerging therapies under investigation include chaperone molecules targeting misfolded nephrin mutants and antisense oligonucleotides for specific splice-site variants, though none are yet approved for clinical use. ACE inhibitors or ARBs are generally avoided in infancy due to hemodynamic instability and lack of proven renoprotection in this setting; their use remains controversial and should only occur in older, stable children with preserved GFR and careful BP monitoring.

Surgical intervention is definitive for most infants with CNS. Bilateral nephrectomy—performed laparoscopically or open between 3–12 months of age—is increasingly adopted prior to kidney transplantation to eliminate persistent proteinuria, reduce infection burden (e.g., recurrent peritonitis from ascites), decrease thromboembolic risk, and improve nutritional status and growth velocity. Post-nephrectomy, patients transition to maintenance dialysis (peritoneal dialysis preferred in infants due to cardiovascular tolerance and technical feasibility) until transplantation. Kidney transplantation remains the only curative option, with excellent long-term graft survival (>90% at 5 years) when performed after nephrectomy. Recurrence of nephrotic syndrome post-transplant is exceedingly rare in monogenic CNS, distinguishing it from primary focal segmental glomerulosclerosis. Preemptive transplantation—without interim dialysis—is not advised due to poor pretransplant nutritional status and high perioperative morbidity.

China offers distinct advantages in the comprehensive management of CNS. First, national newborn screening programs for hereditary kidney diseases—though still expanding—have enabled earlier identification through targeted gene panels (e.g., NPHS1/NPHS2/WL1 sequencing) available at tertiary centers such as Peking University First Hospital and Shanghai Children’s Medical Center. Second, China’s robust organ allocation system, integrated with the China Organ Transplant Response System (COTRS), ensures equitable access to deceased-donor kidneys, with median wait times for pediatric recipients now under 18 months—comparable to Western benchmarks. Third, Chinese centers have pioneered standardized protocols for infant nephrectomy and peritoneal dialysis catheter placement, achieving >95% technical success rates and <5% major complication incidence. Fourth, cost-effectiveness is notable: government-subsidized biologics (e.g., IVIG for infection prophylaxis), domestically manufactured recombinant erythropoietin, and tiered insurance coverage (including the National Reimbursement Drug List) significantly reduce out-of-pocket burdens. Finally, multidisciplinary CNS clinics—offering integrated genetic counseling, psychosocial support, and telehealth follow-up—have demonstrated improved adherence and reduced hospitalization frequency by 35% in cohort studies.

Recovery and long-term care require lifelong vigilance. Post-transplant, patients need meticulous immunosuppression management (tacrolimus ± mycophenolate mofetil), regular monitoring of trough levels, renal function, and infection markers (CMV, EBV). Growth, bone health, and neurocognitive development must be tracked annually using WHO growth standards and validated developmental tools. Vaccination schedules should be optimized pre-transplant (e.g., pneumococcal, meningococcal, varicella) and adjusted post-transplant per KDIGO guidelines. Families benefit from structured education on recognizing rejection signs (e.g., decreased urine output, fever, graft tenderness), managing dietary sodium, and adhering to medication regimens. Psychosocial support—including peer mentoring networks and school reintegration planning—is integral to quality-of-life preservation. With timely nephrectomy, well-timed transplantation, and coordinated care, over 85% of Chinese children with CNS achieve normal schooling, social integration, and reproductive potential in adulthood—underscoring that CNS, while severe, is a manageable chronic condition rather than a uniformly fatal diagnosis.